

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: LeMaitre Vascular Pty Ltd

主要联系人姓名: Aaron McKeon

主要联系人职务: 董事, 澳大利亚

公司网址: <http://www.lemaitre.com>

公司地址: PO Box 359, North Melbourne VIC 3051

公司已上市

公司简介

LeMaitre Vascular 是一家提供外周血管疾病治疗器械的公司。全球超过 2 千万人的生活受到外周血管疾病影响。LeMaitre Vascular 通过开发、制造、营销一次性和植入式血管器械, 满足血管外科医生这一核心客户的需求。

Bio Nova 有限公司是 LeMaitre Vascular 旗下的一家全资子公司, 在澳大利亚从事 Omniflow II 生物合成人造血管的生产制造。对于临床透析来说, 该人造血管可作为血管旁路和动静脉分流器, 方便透析器连接血管, 且和 ePTFE 相比, 通畅率更高、对感染的抵抗力更强。

关键技术或领先技术

LeMaitre's Omniflow II 生物合成人造血管是将绵羊组织与聚酯纤维网混合而成。该产品为血管旁路术和动静脉分流提供了一个应用生物合成物的解决方案。聚酯纤维网提供了强度和耐久性, 而绵羊组织提高了通畅率和抗感染力, 同时提供了类似血管的生物产品。

类别

设备: 血管外科

关键技术或领先技术的发展阶段

产品已经上市

合作机会

尽管我们的产品目前在澳大利亚和欧洲采取的是直销模式，但我们也在积极地寻找其他市场的经销商——尤其是中国市场。我们近期在上海成立了一个办事处，为 Omniflow II 人造血管以及其他多项血管手术用品寻找经销商。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: LeMaitre Vascular Pty Ltd

Key contact name: Aaron McKeon

Job title of key contact: Director, Australia

Company website address: www.lemaitre.com

Company address: PO Box 359, North Melbourne VIC 3051

The company is Listed.

ABOUT THE COMPANY

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

Bio Nova Pty Ltd, a wholly owned subsidiary of LeMaitre Vascular, is an Australian manufacturer of the Omniflow II Biosynthetic Vascular Graft. This graft is used as a bypass conduit as well as an arteriovenous shunt for dialysis access, and provides an alternative to ePTFE with higher patency rates and better resistance to infection.

KEY OR LEAD TECHNOLOGY

LeMaitre's Omniflow II Biosynthetic Vascular Graft is comprised of ovine tissue incorporated into a polyester mesh, offering a biosynthetic solution to vascular bypass and arteriovenous shunting. The polyester mesh provides the rigidity and durability of synthetics whilst the ovine tissue provides the better patency rates, increased infection resistance, and vein-like handling of biologics.

Category

Devices: Vascular surgery

Point of development of key or lead technology

Product on the market

OPPORTUNITIES SOUGHT

Although our products currently enjoy direct distribution in Australia and Europe, we are seeking to partner with distributors in other markets – China, in particular. We have recently opened an office in Shanghai and are seeking distributors to partner with for the Omniflow II graft as well as several of our other many products for use in vascular surgery.